Magnus Åstrand

7PUBLICATIONS
27CO-AUTHORS
Biologically active moleculesFood properties (incl. characteristics and health benefits)PharmacogenomicsMechanobiologyPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 30, 2026
Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system.

|Oct 01, 2024
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.

J David Smeijer, Victor S Wasehuus, Neeraj Dhaun

|Aug 26, 2024
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease.

Muhammad Waqas Sadiq, Hongtao Yu, Magnus Åstrand

|Jul 26, 2024
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study.

Kathleen Connolly, Richard George, Sami Omar

|Jul 04, 2024
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials.

Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker

|May 28, 2024
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.

Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand

Pageof 2

Frequent Collaborators

3 joint publications

Anne-Kristina Mercier

3 joint publications

Philip Ambery

3 joint publications

Peter J Greasley

2 joint publications

Anders Gabrielsen